Soluble epoxide hydrolase drives ferroptosis and cognitive impairment in Alzheimer’s disease

Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, has emerged as a critical mechanism in pathogenesis of Alzheimer’s disease (AD). However, the upstream regulators linking amyloid pathology to iron dyshomeostasis and redox dysfunction remain incompletely understood. Here, we identify soluble epoxide hydrolase (sEH), encoded by EPHX2 , as a key mediator of ferroptotic vulnerability in AD. Ferroptosis-related gene profiling in induced pluripotent stem cell (iPSC)–derived neural progenitor cells (NPCs) from AD patients revealed dysregulation of iron metabolism and antioxidant pathways, accompanied by elevated EPHX2 expression. In APP/PS1 mice and amyloid-β peptide (Aβ 1 - 42 )–injected mice, hippocampal sEH levels were significantly increased and correlated with iron dyshomeostasis (elevated DMT1, TfR, IRP1, and FTH1, reduced FPN) and impaired ferroptosis defense (reduced SLC7A11, GPX4, and FSP1), as well as cognitive impairment. Targeted redox metabolomics demonstrated cysteine depletion, altered glutathione (GSH/GSSG) balance, and global redox remodeling, indicating dysfunction of the SLC7A11–GSH–GPX4 axis. Pharmacological inhibition of sEH with TPPU or genetic deletion of Ephx2 restored iron homeostasis, normalized glutathione metabolism, reduced reactive oxygen species and lipid peroxidation, and ameliorated cognitive deficits. In AD patient iPSCs, and derived NPCs, sEH inhibition rescued membrane lipid peroxidation and mitigated RSL3-induced loss of cell viability, accompanied by rescued GPX4 expression, suppressed oxidative stress, and attenuated ferroptosis-associated mitochondrial damage. Collectively, these findings establish sEH as an upstream regulator linking amyloid pathology to iron dyshomeostasis, impaired antioxidant defense, and ferroptosis in AD. Targeting sEH effectively restores redox balance and protects against cognitive decline, highlighting sEH inhibition as a promising ferroptosis-based therapeutic strategy for AD.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-17
DOI
https://doi.org/10.3389/fimmu.2026.1944138
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Soluble epoxide hydrolase drives ferroptosis and cognitive impairment in Alzheimer’s disease

Jingrui Liu, Yanting Li, Min Ma, Wei Shan et al.
3 links
Frontiers in Immunology
Alzheimer's disease research and treatments
article

Soluble epoxide hydrolase drives ferroptosis and cognitive impairment in Alzheimer’s disease

Jingrui Liu, Yanting Li, Min Ma, Wei Shan, Xiangge Guo, Hongying Zhao, Jiaxuan Wang, Biqing Cao, Aoyu Hu, Qian Ren, Xumeng Wang, Jiaxin Wang, Kenji Hashimoto, Fanjie Zhou
article en

Abstract

Ferroptosis, an iron-dependent form of regulated cell death driven by lipid peroxidation, has emerged as a critical mechanism in pathogenesis of Alzheimer’s disease (AD). However, the upstream regulators linking amyloid pathology to iron dyshomeostasis and redox dysfunction remain incompletely understood. Here, we identify soluble epoxide hydrolase (sEH), encoded by EPHX2 , as a key mediator of ferroptotic vulnerability in AD. Ferroptosis-related gene profiling in induced pluripotent stem cell (iPSC)–derived neural progenitor cells (NPCs) from AD patients revealed dysregulation of iron metabolism and antioxidant pathways, accompanied by elevated EPHX2 expression. In APP/PS1 mice and amyloid-β peptide (Aβ 1 - 42 )–injected mice, hippocampal sEH levels were significantly increased and correlated with iron dyshomeostasis (elevated DMT1, TfR, IRP1, and FTH1, reduced FPN) and impaired ferroptosis defense (reduced SLC7A11, GPX4, and FSP1), as well as cognitive impairment. Targeted redox metabolomics demonstrated cysteine depletion, altered glutathione (GSH/GSSG) balance, and global redox remodeling, indicating dysfunction of the SLC7A11–GSH–GPX4 axis. Pharmacological inhibition of sEH with TPPU or genetic deletion of Ephx2 restored iron homeostasis, normalized glutathione metabolism, reduced reactive oxygen species and lipid peroxidation, and ameliorated cognitive deficits. In AD patient iPSCs, and derived NPCs, sEH inhibition rescued membrane lipid peroxidation and mitigated RSL3-induced loss of cell viability, accompanied by rescued GPX4 expression, suppressed oxidative stress, and attenuated ferroptosis-associated mitochondrial damage. Collectively, these findings establish sEH as an upstream regulator linking amyloid pathology to iron dyshomeostasis, impaired antioxidant defense, and ferroptosis in AD. Targeting sEH effectively restores redox balance and protects against cognitive decline, highlighting sEH inhibition as a promising ferroptosis-based therapeutic strategy for AD.

Frontiers in ImmunologyVol. 17
Hebei Medical University (CN), Chiba University (JP), Capital Medical University (CN), Southwest Medical University (CN), Soochow University (CN), Beijing Tian Tan Hospital (CN), Third Hospital of Hebei Medical University (CN), First Affiliated Hospital of Zhengzhou University (CN), Center for Forensic Mental Health, Chiba University (JP)
National Natural Science Foundation of China, Natural Science Foundation of Hebei Province, University of California, Davis
Good health and well-being
Alzheimer's disease research and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon